prohibited list comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-12-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
| Property | Value | Notes |
|---|---|---|
| Typical form | Lyophilised powder | Reconstituted before use |
| Storage temperature, dry | -20 °C or below | Desiccated, protected from light |
| Purity determination | Reversed-phase HPLC | Reported as percentage of total peak area |
| Identity confirmation | Mass spectrometry | ESI or MALDI-TOF versus calculated mass |
| Common synonyms | Tβ4 fragment; thymosin beta-4 fragment | Naming varies between suppliers |
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
These metabolic interferences lead to death from multi-system organ failure, probably from necrotic cell death, not apoptosis. A post mortem reveals brick red colored mucosa, due to severe hemorrhage. Although arsenic causes toxicity, it can also play a protective role.
==== China ==== The Chinese patent was scheduled to expire in 2026, but a court ruled in 2022 that all patents on semaglutide were invalid "for reasons related to experimental data availability". Novo Nordisk appealed the ruling and the decision was overturned by the Supreme People's Court. According to Novo Nordisk, under the China–Switzerland Free Trade Agreement, semaglutide is subject to regulatory data protection in China until April 2027, and their Swiss subsidiary holds those rights exclusively. Government records indicate that at least 15 generic versions of semaglutide are being developed for the Chinese market, both for diabetes and weight loss; 11 were in the final stages of clinical trials as of June 2024. Among others, Hangzhou Jiuyuan Gene Engineering, The United Laboratories, CSPC Pharmaceutical Group, Huadong Medicine (which also holds a majority stake in Jiuyuan Gene) and Sihuan Pharmaceutical were all preparing generic offerings.
Isotopes are distinct nuclear species (or nuclides) of the same chemical element. They have the same atomic number (number of protons in their nuclei) and position in the periodic table (and hence belong to the same chemical element), but different nucleon numbers (mass numbers) due to different numbers of neutrons in their nuclei. While all isotopes of a given element have virtually the same chemical properties, they have different atomic masses and physical properties. The term isotope comes from the Greek roots isos (ἴσος "equal") and topos (τόπος "place"), meaning "the same place": different isotopes of an element occupy the same place on the periodic table. It was coined by Scottish doctor and writer Margaret Todd in a 1913 suggestion to the British chemist Frederick Soddy, who popularized the term. The number of protons within the atom's nucleus is called its atomic number and is equal to the number of electrons in the neutral (non-ionized) atom. Each atomic number identifies a specific element, but not the isotope; an atom of a given element may have a wide range in its number of neutrons. The number of nucleons (both protons and neutrons) in the nucleus is the atom's mass number, and each isotope of a given element has a different mass number. For example, carbon-12, carbon-13, and carbon-14 are three isotopes of the element carbon with atomic mass numbers 12, 13, and 14, respectively. The atomic number of carbon is 6, which means that every carbon atom has 6 protons so that the neutron numbers of these isotopes are 6, 7, and 8 respectively.
== Side effects == The most common adverse effects of Lamividine/zidovudine are similar to other NRTI's and includes headache, neutropenia, anemia, nausea, vomiting, myopathy and nail pigmentation. More serious and potentially life-threatening adverse effects reported include lactic acidosis with hepatic steatosis, but this rare adverse event is mostly associated with Zidovudine. HIV-positive patients with chronic hepatitis B virus (HBV) infections are at risk for potential flares of hepatitis that can occur with abrupt discontinuation of Lamividine/zidovudine because Lamivudine is also used in low doses for treatment against active HBV.
Sources: en.wikipedia.org
== History == Cellulose was discovered in 1838 by the French chemist Anselme Payen, who isolated it from plant matter and determined its chemical formula. Cellulose was used to produce the first successful thermoplastic polymer, celluloid, by Hyatt Manufacturing Company in 1870. Production of rayon ("artificial silk") from cellulose began in the 1890s and cellophane was invented in 1912. Hermann Staudinger determined the polymer structure of cellulose in 1920. The compound was first chemically synthesized (without the use of any biologically derived enzymes) in 1992, by Kobayashi and Shoda.
==== Absorption ==== Sumatriptan is administered in several forms: tablets, subcutaneous injection, and nasal spray. Oral administration (as succinate salt) has low bioavailability, partly due to presystemic metabolism—some of it gets broken down in the stomach and bloodstream before it reaches the target arteries. There is no simple, direct relationship between sumatriptan concentration (pharmacokinetics) per se in the blood and its anti-migraine effect (pharmacodynamics). This paradox has, to some extent, been resolved by comparing the rates of absorption of the various sumatriptan formulations, rather than the absolute amounts of drug that they deliver.
=== Photodegradation === Additionally, DBNPA is prone to light-induced degradation, especially when exposed to ultraviolet (UV) radiation. Photocatalytic breakdown leads to debromination and the formation of less reactive intermediates, further accelerating its degradation in aqueous systems.
== Measurements and tests == The nitrogen by o-phthaldialdehyde assay (NOPA) is used to measure available primary amino acids in grape juice using a spectrophotometer that can measure at 335 nm wavelength. Since the assay only measures primary amino acids, the results won't include proline or ammonia concentrations. Proline can be separately measured with an assay that uses ninhydrin to react with the amino acid in the presence of formic acid, yielding a compound that can be absorbed at 517 nm.
In 1895, a plan to take Johannesburg, and end the control of the Transvaal government, was hatched with the connivance of Cape Prime Minister Rhodes and Johannesburg gold magnate Alfred Beit. A column of 600 armed men was led over the border from Bechuanaland towards Johannesburg by Leander Starr Jameson, the Administrator in Rhodesia of the British South Africa Company, of which Rhodes was the chairman. The column, mainly made up of Rhodesian and Bechuanaland British South Africa Policemen, was equipped with Maxim machine guns and artillery pieces. The plan was to make a three-day dash to Johannesburg and trigger an uprising by the primarily British expatriate uitlanders, organised by the Johannesburg Reform Committee, before the Boer commandos could mobilise. However, the Transvaal authorities had warning of the raid and tracked it from when it crossed the border. Four days later, the dispirited column was surrounded near Krugersdorp, within sight of Johannesburg. After a skirmish in which the column lost 65 killed and wounded—while the Boers lost one man—Jameson's men surrendered and were arrested. The botched raid had repercussions throughout southern Africa and Europe. In Rhodesia, the departure of so many policemen enabled the Matabele and Mashona peoples' rising against the British South Africa Company. The rebellion, known as the Second Matabele War, was suppressed only at a great cost. A few days after the raid, the German Kaiser sent the "Kruger telegram", congratulating President Kruger and the government of the South African Republic on their success.
Sources: en.wikipedia.org
This can be avoided by breathing air into the mask through the nose. Goggles covering only the eyes are not suitable for deep diving as they cannot be equalised. Dry suit squeeze. The main risk is skin getting pinched and bruised by folds of the dry suit when squeezed on descent. Most dry suits can be equalised against squeeze via a manually operated valve fed from a low pressure gas supply. Air must be manually injected during the descent to avoid squeeze and is manually or automatically vented on the ascent to maintain buoyancy control. Diving helmet squeeze: Helmet squeeze will occur if the gas supply hose is severed above the diver and the non-return valve at the helmet gas inlet fails or is not fitted. Severity will depend on the hydrostatic pressure difference. A very rapid descent, usually by accident, may exceed the rate at which the breathing gas supply can equalise the pressure causing a temporary squeeze. The introduction of the non-return valve and high maximum gas supply flow rates have all but eliminated both these risks. In helmets fitted with a neck dam, the dam will admit water into the helmet if the internal pressure gets too low; this is less of a problem than helmet squeeze but the diver may drown if the gas supply is not reinstated quickly. This form of barotrauma is avoidable by controlled descent rate, which is standard practice for commercial divers, who will use shotlines, diving stages and wet bells to control descent and ascent rates.
Trifluridine (also called trifluorothymidine; abbreviation TFT or FTD) is an anti-herpesvirus antiviral drug, used primarily as prescription eyedrops. It was sold under the trade name Viroptic by Glaxo Wellcome, now merged into GlaxoSmithKline. The brand is now wholly owned by King Pharmaceuticals. Trifluridine was approved for medical use in 1980. It is also a component of the anti-cancer drug trifluridine/tipiracil, which is taken by mouth.
=== RNAi therapeutics === Just after Fire and Mello's ground-breaking discovery, Elbashir et al. discovered, by using synthetically made siRNA, it was possible to target the silencing of specific sequences in a gene, rather than silencing the entire gene. Only a year later, McCaffrey and colleagues demonstrated that this sequence-specific silencing had therapeutic applications by targeting a sequence from the Hepatitis C virus in transgenic mice. Since then, multiple researchers have been attempting to expand the therapeutic applications of RNAi, specifically looking to target genes that cause various types of cancer. By 2006, the first applications to reach clinical trials were in the treatment of macular degeneration and respiratory syncytial virus. Four years later the first-in-human Phase I clinical trial was started, using a nanoparticle delivery system to target solid tumors. The FDA approved the first siRNA-based drug (patisiran) in 2018. Givosiran and lumasiran later won FDA approval for the treatment of AHP and PH1 in 2019 and 2020, respectively. Inclisiran received EMA approval in 2020 for the treatment of high cholesterol and is currently under review by the FDA.
=== Pregnancy === Valproate is a teratogen. Teratogens can cause birth defects. Valproate is restricted for all women under age 55 in the United Kingdom and European Union. It has a black box warning for pregnancy in the United States. There are also restrictions for men. Children fathered by men taking valproate have a higher risk of neurodevelopmental disorders. Valproate is restricted for men under age 55 in the United Kingdom and European Union. The restrictions require two specialists to agree that there is no other effective or tolerated treatment for the patient.
Its head was nearly destroyed, and only the stumps of two arms were visible ... The body, as it lies somewhat imbedded in the sand, is 18 feet long and about 7 feet wide, while it rises 3+1⁄2 feet above the sand ... The weight of the body and head would have been at least four or five tons. If the eight arms held the proportions usually seen in smaller species of the octopus, they would have been at least 75 to 100 feet in length and about 18 inches in diameter at the base. On January 16, the Tatler, a local news sheet that reported on the visitors to St. Augustine hotels, ran a story about the stranded creature. It restated Verrill's original identification of the carcass as a giant squid. It read:
Sources: en.wikipedia.org
Sealed, desiccated and protected from light, at -20 °C or lower for long-term storage. Short-term storage at refrigerator temperature is common in working laboratories.
Synthesis routes, purification steps and the analytical method used all affect the reported figure. A purity number is only comparable when the chromatographic conditions and detection wavelength are stated.
It reports what the supplier measured on a sample, which is useful but not absolute. Independent mass confirmation on the received lot is the more reliable check.
The dry powder is normally kept at -20 °C, protected from light and moisture. Reconstituted solutions are often divided into aliquots and stored at -80 °C to reduce freeze-thaw damage.